3-[3-(2-cyclopropyl-pyridin-4-yl)-phenyl]-3-oxo-propionic acid tert-butyl ester | 579476-64-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-[3-(2-cyclopropyl-pyridin-4-yl)-phenyl]-3-oxo-propionic acid tert-butyl ester
• 英文别名: tert-butyl 3-[3-(2-cyclopropylpyridin-4-yl)phenyl]-3-oxopropanoate
• CAS: 579476-64-5
• 化学式: C₂₁H₂₃NO₃
• 分子量: 337.419
• InChiKey: ZDROZOXDJUOZLN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  56.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-氨基-5-甲基-4-(三氟甲基)苯基氨基甲酸叔丁酯 、 3-[3-(2-cyclopropyl-pyridin-4-yl)-phenyl]-3-oxo-propionic acid tert-butyl ester 以Obtained as an amorphous off-white substance (328 mg, 79%)的产率得到(2-{3-[3-(2-cyclopropyl-pyridin-4-yl)-phenyl]-3-oxo-propionylamino}-5-methyl-4-trifluoromethyl-phenyl)-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Dihydro-benzo[b][1,4]diazepin-2-one derivatives

  摘要：

  本发明涉及公式1中的二氢苯并[b][1,4]二氮杂环己酮衍生物，其中R1，R2，X和Y如规范中所定义，R3是一个含有1至3个氮原子的六元芳香杂环或一种如规范中进一步定义的吡啶-N-氧化物。本发明还涉及包含这些化合物的药物、它们的制备过程以及它们用于制备用于治疗或预防急性和/或慢性神经系统疾病的药物。

  公开号：

  US20030166639A1
• 作为产物：
  描述：

  [2-nitro-5-(2,2,2-trifluoro-ethoxy)-4-trifluoromethyl-phenyl]-carbamic acid tert-butyl ester 、 3-氰基苯硼酸 在 palladium diacetate 碳酸氢钠 、 三苯基膦 作用下， 以 乙二醇二甲醚 、 正庚烷 、 水 、 乙酸乙酯 为溶剂， 生成 3-[3-(2-cyclopropyl-pyridin-4-yl)-phenyl]-3-oxo-propionic acid tert-butyl ester
  参考文献：
  名称：

  Dihydro-benzo[b][1,4]diazepin-2-one derivatives

  摘要：

  这项发明涉及公式为1的二氢苯并[b][1,4]二氮杂二氢吡嗪-2-酮衍生物，其中R 1 ，R 2 ，X和Y如规范中所定义，R 3 是含有1至3个氮原子的六元芳香杂环或如规范中进一步定义的吡啶-N-氧化物。该发明还涉及含有这些化合物的药物、它们的制备方法以及它们用于制备治疗或预防急性和/或慢性神经系统疾病的药物。

  公开号：

  US20030166639A1

文献信息

• DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1474416A1

  公开（公告）日：2004-11-10
• US6949542B2
  申请人：——

  公开号：US6949542B2

  公开（公告）日：2005-09-27
• [EN] DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS<br/>[FR] DERIVES DE DIHYDROBENZODIAZEPINE-2-ONE UTILES DANS LE TRAITEMENT DES TROUBLES NEUROLOGIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2003066623A1

  公开（公告）日：2003-08-14

  This invention relates to dihydro-benzo [b] [1, 4] diazepin-2-one derivatives of the general formula: (Formula I); wherein R1, R2, X and Y are as defined in the specification and R3 is a six-membered aromatic heterocycle containing 1 to 3 nitrogen atoms or a pyridine-N-oxide as further defined in the specification. The invention further relates to medicaments containing these compounds, a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurological disorders.
• Dihydro-benzo[b][1,4]diazepin-2-one derivatives
  申请人：——

  公开号：US20030166639A1

  公开（公告）日：2003-09-04

  This invention relates to dihydro-benzo[b][1,4]diazepin-2-one derivatives of the formula 1 wherein R 1 , R 2 , X and Y are as defined in the specification and R 3 is a six-membered aromatic heterocycle containing 1 to 3 nitrogen atoms or a pyridine-N-oxide as further defined in the specification. The invention further relates to medicaments containing these compounds, a process for their preparation as well as their use for preparation of medicaments for the treatment or prevention of acute and/or chronic neurological disorders.

  这项发明涉及公式为1的二氢苯并[b][1,4]二氮杂二氢吡嗪-2-酮衍生物，其中R 1 ，R 2 ，X和Y如规范中所定义，R 3 是含有1至3个氮原子的六元芳香杂环或如规范中进一步定义的吡啶-N-氧化物。该发明还涉及含有这些化合物的药物、它们的制备方法以及它们用于制备治疗或预防急性和/或慢性神经系统疾病的药物。
• Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2/3 antagonists
  作者：Thomas J. Woltering、Jürgen Wichmann、Erwin Goetschi、Frédéric Knoflach、Theresa M. Ballard、Jörg Huwyler、Silvia Gatti

  DOI：10.1016/j.bmcl.2010.09.125

  日期：2010.12

  This study completes a series of papers devoted to the characterization of the non-competitive mGluR2/3 antagonist properties of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives with particular emphasis on derivatizations compatible with brain penetration and in vivo activity. Especially the compounds bearing a para-pyridine consistently showed in vivo activity in rat behavioral models after oral administration, for example, blockade of the mGluR2/3 agonist LY354740-induced hypoactivity and improvement of a working memory deficit induced either by LY354740 or scopolamine in the delayed match to position task (DMTP). Moreover, combination studies with a cholinesterase inhibitor show apparent synergistic effects on working memory impairment induced by scopolamine. (C) 2010 Elsevier Ltd. All rights reserved.